| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.26 | 0.04 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.3 | 0.04 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.073 | 0.04 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | -0.071 | 0.04 |
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | 0.27 | 0.04 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.095 | 0.04 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.05 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.072 | 0.05 |